Wintermute compounds are currently being developed for treating skin infections and wounds, including those caused by Methicillin-resistant Staphylococcus aureus MRSA and other drug-resistant bacteria. Skin infections are among the most common diseases worldwide, placing an immense burden on global healthcare. In 2010, skin infection ranked 4th among all diseases for years lost due to disability (YLD). It is estimated that up to 70% of all people will suffer one or more skin diseases during their lifetime. The micro-organism responsible for the majority of skin infections is Staphylococcus aureus, of which over 60% are MRSA strains (known as “golden staph”).
At Wintermute Biomedical, we are performing leading-edge research and development into the discovery of next-generation therapeutics and consumer products to prevent and combat infectious diseases. In addition to progressing Wintermute compounds for treating skin infections, we are actively researching, developing and testing:
Antibacterials, anti-virals and anti-fungals.
Systemic therapeutics, including for the treatment of respiratory disease and blood stream infections.
Medical device coatings for infection control.
Wintermute compounds are in pre-clinical development, and are anticipated to enter clinical trials soon.
Our team won’t rest until Wintermute compounds are available to the many patients who desperately need it.